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Discovery of Platelet-Type 12-Human Lipoxygenase Selective
Inhibitors by High-Throughput Screening of Structurally Diverse
Libraries
Joshua D. Deschamps, Jeffrey T. Gautschi, Stephanie Whitman, Tyler A. Johnson, Nadine
C. Gassner, Phillip Crews, and Theodore R. Holman*
Department of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064
Abstract
Human lipoxygenases (hLO) have been implicated in a variety of diseases and cancers and each hLO
isozyme appears to have distinct roles in cellular biology. This fact emphasizes the need for
discovering selective hLO inhibitors for both understanding the role of specific lipoxygenases in the
cell and developing pharmaceutical therapeutics. To this end, we have modified a known
lipoxygenase assay for high-throughput (HTP) screening of both the National Cancer Institute (NCI)
and the UC Santa Cruz marine extract library (UCSC-MEL) in search of platelet-type 12-hLO (12-
hLO) selective inhibitors. The HTP screen led to the characterization of five novel 12-hLO inhibitors
from the NCI repository. One is the potent but non-selective michellamine B, a natural product,
antiviral agent. The other four compounds were selective inhibitors against 12-hLO, with three being
synthetic compounds and one being α-mangostin, a natural product, caspase-3 pathway inhibitor. In
addition, a selective inhibitor was isolated from the UCSC-MEL (neodysidenin), which has a unique
chemical scaffold for an hLO inhibitor. Due to the unique structure of neodysidenin, steady-state
inhibition kinetics were performed and its mode of inhibition against 12-hLO was determined to be
competitive (Ki = 17 µM) and selective over reticulocyte 15-hLO-1 (Ki 15-hLO-1/12-hLO > 30).
Keywords
lipoxygenase; high-throughput; NCI; α-mangostin; michellamine B; neodysidenin; dysidenin;
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Introduction
Human Lipoxygenases (hLOs) are non-heme, iron-containing enzymes that catalyze the
dioxygenation of polyunsaturated fatty acids to their hydroperoxy acids1 and have been
implicated in several diseases involving inflammation, immune disorders and various types of
cancers.2–4 The reticulocyte 15–hLO-1 (15-hLO-1) has been implicated in colorectal5 and
prostate6 cancers, while platelet-type 12–LO has been implicated in pancreatic,7 breast8, 9
and prostate cancers.10, 11 In contrast, prostate epithelial 15-hLO-2 (15-hLO-2) appears to be
anti-tumorigenic in prostate cancer,12 highlighting the need for specific LO inhibitors.
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There are three isozymes of human 12-LO, platelet-type, leukocyte and epidermal, which show
distinct biochemical and inhibitory properties.13–15 Platelet-type 12-hLO (12-hLO) is one of
the most commonly expressed arachidonic acid metabolizing enzymes in human cancer cells.
9, 16–18 Enhanced expression of 12-hLO has been observed in many cancers17 and it is
thought to promote angiogenesis,19 cell migration,20 cell adhesion,21 endothelial cell
retraction,22 and inhibition of apoptosis,23 all properties essential for tumor growth and
metastasis.16 These broad implications in cancer regulation24 underscore the need for small
molecule inhibitors against 12-hLO, however, relatively few inhibitors, with selectivity ratios
greater than 10 against 15-hLO-1, have been found. Gallocatechin gallate is a 12-hLO selective
inhibitor which has an IC50 of 0.14 µM against 12-hLO and an IC50 15-hLO-1/12-hLO ratio
of greater than 700.25 Hinokitol, a tropolone,26 is also selective against 12-hLO (IC50 = 0.1
µM and an IC50 15-hLO-1/12-hLO ratio > 1000),27 but it unfortunately undergoes a structural
conversion upon exposure to light, making it unsuitable as a drug lead. Baicalein has
historically been thought of as a 12-hLO selective inhibitor but this is not the case as seen by
recent in vitro data.28 The lack of 12-hLO specific inhibitors in the literature is also reflected
in our screening of the UC Santa Cruz marine extract library (UCSC-MEL). Over 20 hLO
inhibitors have been characterized from our of marine natural products (MNP) library, but only
a few are selective against 12-hLO and none have selectivities greater than 10.29–33 The most
selective 12-hLO inhibitors discovered to date in our laboratories are (-)-7-N-
methyldibromophakellin33 (IC50 15-hLO-1/12-hLO = 5), jaspic acid29 (IC50 15-hLO-1/12-
hLO = 2) and hyrtenone A29 (IC50 15-hLO-1/12-hLO = 2).
In the current investigation, we have modified a known lipoxygenase assay34 to a high-
throughput (HTP), 384-well format and screened four different compound libraries for 12-hLO
selective inhibitors. These include the National Cancer Institute (NCI) chemical repository,
which contains the NCI natural product library (NCI-NPL) (235 structurally diverse
compounds), the NCI diversity library (NCI-DL) (1990 known pharmacophores) and the NCI
mechanistic library (NCI-ML) (879 known growth inhibitors of tumor cell lines) and a portion
of the UCSC-MEL (272 sponge extracts from approximately 90 different sponges). By this
screen, we have discovered five novel 12-hLO selective inhibitors and characterized their
inhibitory properties.
Results
Expression and Purification of Lipoxygenases
Human platelet-type 12-hLO (12-hLO), human reticulocyte 15-hLO-1 (15-hLO-1) and human
prostate epithelial 15-hLO-2 (15-hLO-2) were purified utilizing SF9 insect cells with
approximate yields of 50 mg/L. The ICP-MS data indicated that 12-hLO had 12 ± 1% iron
content, 15-hLO-1 had 24 ± 2% iron content and 15-hLO-2 had 35 ± 5% iron content. All
kinetics data were adjusted for iron content.
High-Throughput Screening Assay Analysis
Initial HTP screening of the 3104 NCI compounds and the 272 sponge extracts was performed
against both 12-hLO and 15-hLO-1. Utilizing the Fe3+/xylenol orange screening method,34,
35 we miniaturized it to an HTP 384-well format and discovered six 12-hLO selective inhibitors
from the NCI library; NSC30552, NSC125034, NSC172033, NSC292213, NSC617570,
NSC661755 (Table 1). Four organo-mercurial compounds (NSC20410, NSC268879,
NSC321237 and NSC321239) were also found to be selective, but not pursued further due to
their potentially toxic side effects.36 Screening of the UCSC-MEL only revealed one clear 12-
hLO selective crude extract, the dichloromethane fraction (02155FD) from the sponge Dysiden
herbacea (Table 1). All other sponge extracts or semi-pure fractions showed little or no
selective inhibition against 12-hLO.
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Verification of Hits from Initial High-Throughput Screening Assay
Manual, continuous assays, with one inhibitor concentration, were performed on the six NCI
compounds and the one marine sponge extract from the HTP screen to verify their selectivity
against 12-hLO (Table 1). We determined that NSC30552, NSC172033, NSC292213 and
NSC617570 were selective inhibitors against 12-hLO. NSC661755 was not selective but was
a potent inhibitor against both 12-hLO and 15-hLO-1. NSC125034, however, did not inhibit
either LO isozyme, even though it did show potency in the HTP screen (Table 1). It is unclear
why the HTP displayed this false positive, but one possibility is the differences in reaction
conditions and inhibitor concentrations between the HTP and manual assays. The 02155 FD
fraction from the UCSC-MEL was selective against 12-hLO (Table 1).
IC50 Analysis
The IC50 analysis of 12-hLO, 15-hLO-1 and 15-hLO-2 was performed on the NCI and UCSC
compounds as previously described31 and were consistent with the one point, manual assay.
Four compounds, NSC30552, NSC172033, NSC292213 and NSC617570, had selectivity
ratios greater than 5 (Table 2). Compound NSC661755 was determined to be non-selective
with an IC50 15-hLO-1/12-hLO ratio of 2. None of these compounds inhibited 15-hLO-2, with
all exhibiting IC50 values greater than 50 µM (Table 2). These compounds were analyzed by
LC-MS and shown to be greater than 95% pure as received from NCI. For the UCSC-MNP,
neodysidenin had an IC50 greater than 100 µM against 12-hLO and had no effect against 15-
hLO-1 (Figure 2, Table 2).
Neodysidenin Steady-State Inhibition Studies of 12-hLO and 15-hLO-1
For 12-hLO, neodysidenin showed competitive inhibition. The plots Km(app) / kcat(i) (slope)
and Km(app) versus neodysidenin concentration for 12-hLO are shown in Figure 2A and 2B,
respectively. Both plots showed linear graphs with similar inhibition constants, where the
Km/kcat plot yields a Ki of 16 ± 1 µM (Figure 2A) and the Km(app) plot yields a Ki of 18 ± 1
µM (Figure 2B), indicating competitive inhibition.37 The average of the Ki values is 17 ± 1
µM (Table 3). It is interesting to note that these inhibition constants are lower than those seen
from the IC50 data. It is unclear why there is this discrepancy, except for the fact that the steady-
state data is much more accurate than the IC50 data. Neodysidenin had no effect on 15-hLO-1
at concentrations up to 500 µM, indicating no appreciable inhibition (Table 3). The specific
activities of both 12-hLO and 15-hLO-1 were comparable to our previously published values.
38
Dysidenin Steady-State Inhibition Studies of 12-hLO and 15-hLO-1
Dysidenin was obtained from the UC Santa Cruz marine compound library for SAR
comparison to neodysidenin. For 12-hLO, plots of Km(app) / kcat(i) (slope) and 1 / kcat(i) (y-
intercept) versus dysidenin are shown in Figure 3A and 3B.37 The plots are linear and give
two different inhibitor constants, Ki and Ki’, which are defined as the equilibrium constant of
the dissociation of inhibitor from the catalytic site and a secondary site, possibly an allosteric
binding site,39 respectively. The Km(app) / kcat(i) versus [I] plot yields a Ki of 9 ± 2 µM, while
1 / kcat(i) versus [I] plot yields a Ki’ of 55 ± 24 µM (Table 3), representing a linear mixed-type
inhibition.37 For 15-hLO-1, dysidenin also showed linear mixed-type inhibition with a Ki of
8 ± 3 µM and a Ki’ of 54 ± 27 µM (Table 3).
Discussion
For many years, our laboratories have been interested in discovering hLO selective inhibitors,
however, none have had a greater IC50 15-hLO-1/12-hLO ratio than 5.29, 30 To accelerate our
ability to screen for 12-hLO selective inhibitors, we modified the known xylenol orange
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lipoxygenase assay34, 35, 40–42 into an HTP 384-well format and screened the 3104
compounds of the NCI mechanistic, diversity and natural product library (Scheme 1). Sixteen
potent 12-hLO inhibitors were found, 10 being relatively selective, which represents a 0.3%
proportion of selective 12-hLO inhibitors. By comparison, the HTP screen of the NCI
repository found 43 potent inhibitors against 15-hLO-1, with 33 being selective, representing
a 1.4% proportion of selective inhibitors. The lower percentage of 12-hLO selective inhibitors
versus 15-hLO-1 selective inhibitors is consistent with our previous work with UCSC-MNPs
and illustrates the difficulty in targeting 12-hLO. Of the 10 selective 12-hLO inhibitors found
by the HTP screen, 4 were organo-mercurials, which were discarded due to potential toxicity.
36 The remaining 6 were subjected to secondary manual screening, with NSC125034 losing
all inhibitory activity and NSC661755 (michellamine B)43 losing its inhibitory selectivity,
however, not its potency (IC50 for 12-hLO is 4.9 µM and 7.6 µM for 15-hLO-1). Michellamine
B is a natural product, anti-HIV agent, which inhibits protein kinase C (PKC)44 and has been
implicated as a potential anti-cancer treatment. Our discovery that michellamine B inhibits
both 12-hLO and 15-hLO-1 but does not inhibit 15-hLO-2, may stimulate further interest in
its study as an anti-cancer agent.
The remaining 4 compounds (NSC30552, NSC172033, NSC292213 and NSC617570) are all
selective against 12-hLO but have little structural similarity. The only common structural
feature is that they all contain two or more aromatic hydroxyl groups, which typically reduce
the active site ferric iron of LO.45 The most unusual inhibitor is NSC617570, a nickel complex,
which is not only exceptionally potent (IC50 = 190 nM), but also has a high IC50 15-hLO-1/12-
hLO ratio of 2631. Its structure is not amenable to drug discovery but it could be useful as a
molecular probe against LO activity in the cell. Of the remaining three compounds, Lipinski’s
“rule of five” (LRoF) was used to assess the extent that their physical and structural features
were drug-like46 and only NSC292213, a known 5-aminoimidazole-4-carboxamide
ribonucleotide transformylase inhibitor,47 adhered to LRoF (Table 4). NSC172033, a known
human mitotic kinesin inhibitor,48, 49 has a large MW (674.018 Da), while NSC30552 has a
cLogP greater than 5, both values violate LRoF. Despite its high cLogP, NSC30552 (α-
mangostin) is used as a traditional medicine for the treatment of skin infections, wounds and
diarrhea50 and has been shown to inhibit sphingomyelinase.51,52 α-Mangostin also inhibits
cyclooxygenase53 and the caspase-3 pathway through direct inhibition of Ca(II)-ATPase,
inducing apoptosis.54 It is interesting to note that 12-hLO inhibitors also induce apoptosis
through the caspase-3 pathway,55 which could imply that α-mangostin has dual activity against
cancer proliferation. This hypothesis should be tempered by the fact that its IC50 15-hLO-1/12-
hLO ratio is only 5, however further study is still warranted.
The HTP screening of the 272 sponge extracts from the UCSC-MEL yielded only one extract,
which was selective against 12-hLO (02155 FD). Fractionation of this crude extract yielded
the 12-hLO inhibitor, neodysidenin, an isomer of dysidenin, a known inhibitor of iodide
transport in thyroid cells.56 Steady-state inhibition kinetics demonstrated that neodysidenin
was a competitive inhibitor against 12-hLO (Ki = 17 ± 1 µM) but it was inactive against 15-
hLO-1 (Ki > 500 µM). Even though the potency of neodysidenin is relatively low, its selectivity
against 12-hLO is the highest recorded for our MNP hLO inhibitors (Ki 15-hLO-1/12-hLO
ratio > 30). In contrast, steady-state inhibition kinetics determined that dysidenin was a linear
mixed inhibitor against both 12-hLO (Ki = 9 ± 2 µM, Ki ’ = 55 ± 24 µM) and 15-hLO-1 (Ki =
8 ± 3 µM, Ki’ = 54 ± 27 µM). These data suggest that neodysidenin binds only to the active
site of 12-hLO, while dysidenin binds to both the active site and a secondary site of both 12-
hLO and 15-hLO-1, possibly the allosteric site.57 This is an intriguing result because
neodysidenin and dysidenin58 are parallel in structure and differ only in the regiochemistry of
the N-methyl, with epimeric geometries at carbon-13. These minor structural changes modulate
hLO selectivity from 1 for dysidenin to >30 for neodysidenin. Nevertheless, this gain in
selectivity for neodysidenin has a concomitant loss of potency, with neodysidenin’s Ki values
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to the active site of 12-hLO being twice that of dysidenin. A similar effect was seen previously
in our laboratories, where hyrtenone A, which is selective against 12-hLO, is over 10-fold less
potent than its analogue, puupehenone, a selective 15-hLO-1 inhibitor.29 The potency and
selectivity of neodysidenin against 12-hLO versus 15-hLO-1 make it a novel class of LO
inhibitor that could potentially be optimized by further structural modifications to increase its
potency against 12-hLO, while maintaining its high selectivity. In addition, it will be important
to determine whether neodysidenin is also selective against platelet-type 12-hLO versus
leukocyte and epidermal 12-hLO.
Conclusion
In summary, our data provides a number of important insights regarding rapid inhibitor
discovery against platelet-type 12-hLO. First, we demonstrated that the xylenol orange assay
can be miniaturized to an HTP 384-well format, which greatly accelerates our discovery of
platelet-type 12-hLO selective inhibitors versus 15-hLO-1. Second, the NCI repository
contains 4 potent and selective 12-hLO inhibitors, which can be used as investigative tools for
the role of hLO in the cell. Third, neodysidenin represents a novel structural class of LO
inhibitors that is selective against platelet-type 12-hLO and whose potency could be optimized
with structural modifications.
Experimental
Materials
Arachidonic acid (AA), linoleic acid (LA), xylenol orange and ferrous ammonium sulfate were
purchased from Sigma-Aldrich Chemical Company. Mechanistic, diversity and natural
products 384-well library plates were obtained from the National Cancer Institute (NCI).
Larger quantities of selected compounds required for further inhibition investigations were
also obtained from the NCI and shown to be pure with a Thermo LCQ LC-MS. The marine
sponge crude extracts and dysidenin were obtained from the marine natural products repository
at UCSC. All other chemicals were reagent grade or better and were used without further
purification.
Reverse phase-HPLC purification of AA and LA
AA and LA were purified as published,38 using a Higgins Preparative Haisil (250 × 10mm)
C-18 5 µM column. An isocratic elution of 85% A and 15% B (Solvent A: 99.9% MeOH 0.1%
acetic acid, Solvent B: 99.9% H2O and 0.1% acetic acid) was used to purify the fatty acids and
both were stored in 95% EtOH at -20°C.
Expression and Purification of Lipoxygenases
Human platelet-type 12-lipoxygenase (12-hLO) and reticulocyte 15-lipoxygenase (15-hLO-1)
are N-terminus, His6-tagged proteins and were expressed and purified as described previously.
29 The SF9 expression vector for human prostate epithelial 15-lipoxygenase-2 (15-hLO-2)
was constructed as follows. The previously published plasmid, pCRII-TOPO- 15-hLO-2,12
was cut with EcoRI to liberate the 15-hLO-2 fragment. This 15-hLO-2 fragment was then
ligated into EcoRI cut, pFastBac1 (GibcoBRL) to generate the complete plasmid, pFastBac-15-
hLO-2, which was digested to determine the correct orientation. The pFastBac-15-hLO-2 was
then transposed into a recombinant FastBac bacmid by DH10Bac cells (GibcoBRL) and then
transfected into SF9 cells, as described in the product literature for pFastBac1 (GibcoBRL).
The virus was subsequently amplified to 2×1010 plaque forming units (pfu), added to SF9 cells
(2×106 cells/ml) at a concentration of 2×107 pfu/ml and allowed to shake for 72 hours. The
cells were then harvested and frozen. 15-hLO-2 was purified by douncing the thawed cells and
loading the cell extracts onto a 20 mL Macro-prep High Q, strong anion exchange column,
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from Bio-Rad. The protein was eluted with a 50-300 mM sodium chloride gradient. The
collected fractions, containing 95% pure protein and 5% glycerol, were then frozen at −80° C.
Subsequent thawing produced no decrease in enzymatic activity. Iron contents of all three
lipoxygenase enzymes were determined with a Finnigan inductively coupled plasma mass
spectrometer (ICP-MS), using cobalt-EDTA as an internal standard. Enzyme iron
concentrations were compared to standardized iron solutions.
Collection and Identification of Dysidea herbacea
The crude extract (02155FD) was obtained in 2002 near Duchess Island, Papua New Guinea
(9_57.228 S, 150_51.059 E) using SCUBA at -30 ft (UCSC coll. nos. 02155). The sample was
fan shaped, green in color with a purple underside, and had a ridged surface punctuated with
digitate projections (3–5 cm). Taxonomy of 02155 was performed by R.W.M. van Soest
(Zoological Museum of Amsterdam) and was identified as Lamellodysidea herbacea (order
Dictyoceratida; family Dysideidae). The recent re-classification of the family Dysideidae has
led to the novel genus Lamellodysidea,59 which is marked by its massive, lamellate to digitate
morphology, and thin basal plate. This newly proposed taxonomic nomenclature is
synonymous with many previously designated Dysidea herbacea, and has only recently begun
to enjoy proper usage. Thus, we have chosen to indicate these sponges as Dysidea
(Lamellodysidea) herbacea and note that such samples are similar to our previous disclosures
of Dysidea herbacea.60, 61
Extraction and Isolation of Neodysidenin
The D. herbacea collection 02155 was preserved, transported, and stored at 4°C until
processed, as previously described.60, 62 The UCSC Kupchan-like extraction method was
utilized to produce six crude extracts.33 These six crude extracts were then subjected to LCMS
analysis using an HPLC system equipped with a Waters 717plus Autosampler, and Waters 996
photodiode array detector (PDAD), Sedere Sedex 75 evaporative light scattering detector
(ELSD), and a Mariner MS (ESI-TOF-MS). Isotopic distribution patterns from MS were then
used to determine HPLC peaks corresponding to halogenated metabolites and ELSD data
provided approximate relative amounts. It was readily apparent from LCMS that collection
02155 contained a number of polychlorinated species with molecular weights corresponding
to known peptides from D. herbacea. The most abundant chlorinated metabolite in the
dichloromethane crude extract (FD) of the 02155 bulk collection was pursued and identified
as a hexachlorinated species of m/z 544 [M+H]+ by LCMS. Approximately 100 mg of 02155
FD was directly applied to reversed-phase HPLC separation, leading to the isolation of (-)-
neodysidenin (5.0 mg). The following properties of (-)- neodysidenin were compared with
literature values: Neodysidenin: white powder: [α]26D - 52.7° (c 0.10, MeOH); UV ?max
(MeOH) 241 nm; ¹H NMR (500 MHz, CDCL3) d 1.39 (3H, d, J = 6.5 Hz, H-1), 1.50 (H3, d,
J = 6.0 Hz, H-8), 1.69 (3H, d, J = 7.5 Hz, H-14), 1.81a (m), 2.32 (H, m, H-3), 2.34 (H, m, H-6′),
2.62 (H, m, H-7), 2.96 (3H, s, N-Me), 3.09 (H, dd, J = 14.5, 2.0 Hz, H-3′), 3.22 (H, m, H-2),
5.09, (H, ddd, J = 11.5, 8.5, 2.5 Hz, H-5), 6.17 (H, q, J = 7.0 Hz, H-13), 6.80 (H, bd, J = 8.0
Hz, NH), 7.35 (H, d, J = 3.5 Hz, (H-17), 7.75 (H, d, J = 3.5 Hz, H-16); and 13C NMR and
DEPT (125.5 MHz, MeOD) d 15.2 CH3, 15.3 CH3, 15.7 CH3, 29.2 CH3, 34.9 CH2, 38.9
CH2, 49.0 CH, 50.7 CH, 51.5 CH, 51.6 CH, 104.7 C, 105.3 C, 120.0 CH, 141.9 CH, 170.5 C,
171.5 C, 171.6 C. HRESITOFMS [M+H]+ m/z 543.9712 (calcd for C17H24N3O2SCl6
543.9715). a Obscured by overlap.
Dysidenin was obtained from the UCSC-MNP pure compound repository. The following
properties of (-)-dysidenin were compared with literature values: Dysidenin: white powder;
[α]23D - 68° (c 0.034, CHCl3); UV ?max (CHCl3) 248 nm; ¹H NMR (250 MHz, CDCL3) d
1.36 (3H, d, J = 6.5 Hz, H-8), 1.39 (H3, d, J = 6.9 Hz, H-1), 1.59 (H3, d, J = 6.8 Hz, H-14),
1.92 (H, ddd, J =14.8, 10.5, 2.5, 2.22 Hz, H-6′), 2.22 (H, ddq, J =10.5, 6.5, 2.5 Hz, H-7), 2.49
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(H, dd, J = 16.3, 10.0 Hz, H-3′), 2.62 (H, dd, J = 14.8 10.5 Hz, H-6), 3.04 (H, s, H-10), 3.13
(H, dd, J = 16.3, 2.5 Hz, H-3), 3.38 (H, ddq, J = 10.0, 6.5, 2.5 Hz, H-2), 5.36 (H, q, J = 6.8 Hz,
H-13), 5.37 (H, 13 dd, J =10.5, 2.5 Hz, H-5), 6.84 (H, bd, J = 7.0 Hz, N-H), 7.28 (H, d, J = 3.3
Hz, H-17), 7.71, (H, d, J = 3.3 Hz, H-16); 13C NMR (75.5 MHz, CDCl3) d 16.3 (C-8), 17.4
(C-1), 21.9 (C-14), 30.9 (C-10), 31.0 (C-6), 37.5 (C-3), 47.3 (C-13), 51.5 (C-2), 51.9 (C-7),
54.1 (C-5), 105.2 (C-11), 105.6 (C-9), 119.2 (C-17), 142.5 (C-16), 168.9 (C-12), 172.0 (C-15),
172.1 (C-4); LRFABMS (m/z 544 [M+H]+).
High-Throughput Screening Assay
The high-throughput (HTP) screening assay was modified from a previously published
procedure to utilize a 384-well assay plate.34,35 Briefly, the lipid peroxide product (HPETE)
formed by the LO reaction converts ferrous iron (Fe2+) into ferric iron (Fe3+), which forms a
Fe3+/xylenol orange complex that absorbs at 560 nm. The HTP screen was performed as
published earlier with the following modifications.34,35 Reactions with 12-hLO were carried
out in 25 mM Hepes buffer (pH 8.0) in the presence of 0.1% Triton X-100. Reactions with 15-
hLO-1 and 15-hLO-2 were carried out in 25 mM HEPES (pH 7.5) in the presence of 0.1%
Triton X-100. A 30 µM (45 µl) substrate buffer solution (AA for 12-hLO and 15-hLO-2 and
LA for 15-hLO-1) was added to each well using a Thermo Labsystems 384-well Multidrop.
The compounds from the 384 assay plate libraries, dissolved in DMSO, were added using a
specially designed automated liquid pin transfer device from V & P Scientific, which delivers
0.2 µL of sample. The NCI plates are at 10 mM concentrations and the UC Santa Cruz marine
extracts are at 10 mg/ml, which yields final concentrations of inhibitors to be 40 µM and 40
µg/ml for the NCI pure samples and MNP crude extracts, respectively. Using the Multidrop,
the reactions were initiated by adding 5 µL of an enzyme concentration that produces a linear
rate for the duration of the experiment with approximately 40 nM for 12-hLO and 15-hLO-1
(final volume of 50 µL). The reactions were then stopped at approximately 35% completion,
by the addition of the appropriate amounts of regents to give a final concentration of 100 µM
of xylenol orange and 150 µM ferrous ammoniums sulfate in 25 mM H2SO4, with a final
volume of 100 µl in each well. The plates were allowed to shake for 30 minutes in the dark on
an orbital shaker to allow the Fe3+/xylenol orange complex to form. After 30 minutes the plates
were read by measuring the absorption at 560 nm using a Victor2 Perkin-Elmer plate reader.
The negative controls for the assay contained no enzyme and 0.2 µl of DMSO (with no
inhibitor) in the reaction buffer. The positive controls for the assay contained enzyme and 0.2
µl of DMSO in the reaction buffer, as mentioned above. All assays were done in triplicate. The
percent inhibitions were calculated by subtracting the absorbance of the negative controls from
the absorbance of the positive controls. The values were then subtracted from 1 and multiplied
by 100 to get the percent inhibition.
Manual-Initial Screens
The one-point inhibition percentages were determined by following the formation of the
conjugated diene product at 234 nm (ε = 25,000 M¹cm−1) with a Perkin-Elmer Lambda 40 UV/
Vis spectrophotometer at one inhibitor concentration. All reactions were 2 mL in volume and
constantly stirred using a magnetic stir bar at room temperature (23° C) with approximately
40 nM for 12-hLO and 15-hLO and 1 µM for 15-hLO-2. Reactions with 12-hLO were carried
out in 25 mM Hepes buffer (pH 8) in the presence of 0.01% Triton-X-100. Reactions with 15-
hLO-1 and 15-hLO-2 were carried out in 25 mM Hepes buffer (pH 7.5) in the presence of
0.01% Triton-X-100. The concentration of AA (for 12-hLO and 15-hLO-2) and LA (for 15-
hLO-1) were quantitatively determined by allowing the enzymatic reaction to go to completion.
For the NSC compounds, 10 µM inhibitor was used and for the crude sponge extract, 25 µg/
ml was used.
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IC50 Assay
IC50 values were determined using the same method as previously described in the one point,
manual screen section above. IC50 values were obtained by determining the enzymatic rate at
various inhibitor concentrations then plotting them against inhibitor concentration. The data
was fit to a saturation curve and the inhibitor concentration at 50% activity was determined
(IC50). Inhibitors were stored at −20°C in MeOH or DMSO depending on their solubility.
Steady-State Inhibition Kinetics Studies
Lipoxygenase rates were determined using the same method as previously described in the
IC50 section. Michaelis-Menten kinetics were determined for 12-hLO and 15-hLO-1 with their
respective substrates and at varying inhibitor concentrations, from 0.38 to 80 µM. Enzymatic
reactions were initiated by the addition of 5 nM 12-hLO and 9 nM 15-hLO-1. Kinetic data
were obtained by recording initial enzymatic rates at each substrate concentration and then
fitting them to the Michaelis-Menten equation using the KaleidaGraph (Synergy) program. All
inhibitors were studied in separate experiments against each enzyme at least three times to
determine their inhibitor binding constants (Ki and Ki’).37 The Km(app) and kcat(i) values were
obtained from hyperbolic fits at various inhibitor concentrations. The percent error for both
Ki and Ki’ were determined from the linear Km(app) / kcat(i) (slope) and 1 / kcat(i) (y-intercept)
plots, utilizing the LINEST function of Excel (Microsoft).
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Figure 1.
Structures of the UCSC library natural products, neodysidenin (A) and dysidenin (B)
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Figure 2.
Competitive inhibition steady-state kinetic data for Ki determination for 12-hLO with
neodysidenin. (A), Km(app) / kcat(i) (slope) vs. [neodysidenin] µM (B), Km(app) vs.
[neodysidenin] µM.
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Figure 3.
Linear mixed-type inhibition steady-state kinetic data for determination of Ki and Ki’ for 12-
hLO with dysidenin. (A), Km(app) / kcat(i) (slope) vs. [dysidenin] µM (B), 1/kcat(i) (y-intercept)
vs. [dysidenin] µM.
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Scheme 1.
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Table 3
UCSC library compound steady-state inhibition data for 12-hLO and 15-hLO-1.
 Neodysidenin Dysidenin
12-hLO Ki = 17 ± 1 µM Ki = 9 ± 2 µM
Ki’ = 55 ± 24 µM
15-hLO-1 Ki > 500 µM Ki = 8 ± 3 µM
Ki’ = 54 ± 27 µM
15-hLO-1/12hLO > 30 1
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Table 4
Physical and structural features of 12-hLO inhibitors
Compound MW (Da) cLogPa H-bond Acceptors H-bond donors
NSC30552 (α-mangostin) 410.47 6.3 6 3
NSC172033 674.02 9.6 4 4
NSC292213 430.37 4.2 8 4
NSC617570 527.61 1.8 9 6
NSC661755 (michellamine B) 756.90 9.9 10 8
neodysidenin 543.97 4.9 5 2
a
clogP (i.e. miLogP) determined with Molinspiration Calculation Service, www.molinspiration.com.
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